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Abstract 
 
Cancer immunotherapy has advanced with the introduction of anti-PD-1 therapy. Anti-PD-1 
therapy blocks the inhibitory immune checkpoint receptor PD-1, and allows T cells to regain 
their cytotoxic potentials in response to cancerous cells. Amongst the cytotoxic lymphocytes 
other than T cells, natural killer (NK) cells have not been fully explored regarding anti-PD-1 
treatment. With this in mind, our aim was to characterize the immunophenotype of the immune 
cells in patients diagnosed with renal cell carcinoma (RCC), and separate their corresponding 
tumor infiltrating lymphocytes (TILs).  
Altogether, we analyzed the immunophenotype of the T and NK cells and RCC tumor cells 
from 13 RCC patients using flow cytometry. In addition, we tested the function of NK cells 
against RCC cells using various cell line models (NK-92 and RCC cell lines), and monitored 
the cytotoxicity in real time using a cell impedance assay. Based on the results, we suggest that 
patients diagnosed with RCC possess unique immune profiles depending on the individual, but 
also share characteristics regarding the tumor. In addition, NK cells have the potential to 
activate a cytotoxic response to RCC cells. By phenotyping the TILs, potential novel 
biomarkers for immuno-oncological (IO) therapy could be detected, which could aid in 
determining which patients would most likely benefit from immunological therapies such as 
anti-PD-1 treatment.  
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Introduction 
 
 
Among the most common cancer killers in men and women, kidney cancer is within the top 
10, with a lifetime risk of about 1 in 63 (1.6%) for development1. The incidence of kidney 
cancer, especially among the elderly, is on the rise with approximately 908 new cases per 
year and 362 deaths (incidence 2010-2014) are seen annually in Finland2. Although multiple 
therapies that target tumor growth and angiogenesis are effective, they fail at keeping the 
tumors from returning. In adults, clear cell renal cell carcinoma (ccRCC) is the most 
dominant type of the cancer. Early stages of the cancer show hardly noticeable symptoms. 
When symptoms are detected, it is most likely that the cancer has metastasized and reached 
the advanced phase of the disease. Despite the numerous options of treatment other than 
surgery (nephrectomy is surgical procedure of choice), kidney cancer remains difficult to 
treat, thus is yet poorly understood.  
With a current wide variety of chemotherapeutic drugs, only a handful has shown 
responses in RCC. This may be due to the fact that RCC is mostly resistant to radio and 
chemotherapies. Another alternative would be to harness the immune system in treating 
cancer. Initially, cytokine-based immune therapies such as interleukin 2 (IL-2) and interferon 
α (IFNα) have shown to be effective in RCC. However, the suitability of these treatments has 
not been proven ideal due to the toxic adverse effects from the use of high IL-2 
concentrations, and the ineffectiveness of IFNα monotherapy3. Today, a more powerful 
generation of targeted immune therapies are on the rise, namely immune checkpoint 
inhibitors, which are antibodies designed to counteract the molecular pathways that the tumor 
cells participate in evading immune recognition.  
Immune checkpoints are a necessity to the human immune system and are responsible 
for maintaining self-tolerance or the prevention of autoimmunity, as well as the protection of 
tissues against damage in response to pathogenic infections. However, the expression of these 
immune checkpoint proteins may become dysfunctional when they act as an immune 
resistance mechanism from the attack of tumors. Although the human immune system has 
capabilities of targeting and eliminating cancer cells, a fraction of these cancer cells has the 
ability to escape the body’s immunosurveillance by forming tumors and further, metastases. 
One form of escape is the ability of some tumor types to express ligands that inhibit the 
activation of tumor-specific lymphocytes4. The majority of these ligands are those that 
interact with the immune checkpoint pathways responsible for the inhibition of immune 
system signals. Blocking immune checkpoints is a competent approach to cancer therapy 
today. In the case of stage IV melanoma, the drugs nivolumab (Opdivo® BMS) and 
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pembrolizumab (KEYTRUDA®, Merck) have been approved in the EU and Finland, 
functioning as immune checkpoint inhibitors that act to block the inhibition pathway of T cell 
activation. Their mechanism of action is based on inhibiting the programmed death protein 1 
(PD-1) from binding to its ligand, programmed death receptor ligand 1 (PD-L1) in the form of 
monoclonal antibodies (mAbs). The PD-1 receptor is widely expressed on the surface of 
activated T cells and functions as a negative regulator of T cell activation. In addition to 
antigen presenting cells (APCs), tumor cells are also able to express PD-L1 and PD-L2 that 
bind to the PD-1 receptor and inactivate the immune system4. From the initial anti-PD-1 
treatment in melanoma patients, similar regimens have been applied to RCC patients, and 
further, to a broader spectrum of immune checkpoint therapies. With this in mind, it is 
noticeable that PD-1 inhibitors have already been approved in the United States and Europe 
for the treatment of advanced RCC patients, under various stages of clinical development5, 6.  
The human immune system is classified into the adaptive and innate subsystems. The 
adaptive system is responsible for a highly controlled and long-lasting response, and the 
innate for a rapid and unspecific immune response, as well as inducing the functioning of the 
adaptive immune system at the site of action. T cells are major players of the adaptive 
immune system. Furthermore, their lymphocytic division into cytotoxic CD8+ effectors and 
CD4+ helpers make T cells critical to the adaptive and innate immune systems. Due to their 
potential in selectively recognizing peptides derived from all proteins of the cellular 
compartment, T cells show great promise in becoming manipulated for antitumor immunity. 
Their mechanism of action entails the interaction between the T cell receptor (TCR) and the 
pathogenic tumor antigens presented by the major histocompatibility complex (MHC) 
molecules. The engagement of the TCR with the MHC then activates a series of signal 
transduction events that lead to antitumor immunity and activation of the intracellular 
cytotoxic machinery that recognizes and kills that target cancer cells3. The use of one’s own 
immune system in the treatment of cancer and the usage of immune checkpoints offer a great 
capacity to initiate an antitumor immune response, and thus also pave a new way for future 
cancer therapies7.  
Natural Killer (NK) cells belong to the family of cytotoxic lymphocytes that are part 
of the innate immune system and have the ability to spontaneously kill cells that are deemed 
harmful to the host. NK cells are able to migrate, produce and secrete lymphocyte-stimulating 
cytokines at the site of action, acting to protect and guide the immune system8. The cells are 
able to kill their targets without requiring the recognition of the MHC presented on cell 
surfaces9. Based on their functional characterization, NK cells are vital in the prohibition of 
tumor growth as well as metastases. However, malignant cells are still able to surpass this 
checkpoint from the lack in number of NK cells, as well as impairments in their inhibition 
abilities, and decrease in cell signal activation. NK cell activation occurs through a crosstalk 
	 3	
of activating and inhibitory signals that are received on the NK cells. Inhibitory ligands such 
as PD-L1 expressed on the surface of the target tumor cells or APCs prevent NK cells from 
activating4. Therefore, trying to eliminate these signals via the blocking of mAbs such as PD-
1 would restore NK cell activity and function. Currently, immune checkpoints are less studied 
in regard to their function in NK cells. However, it is certain that NK cells are essential in 
responding to various types of cancers and therapeutics so that their functions may be 
improved. One successful case would be the combinatorial treatment of relapsed acute 
myeloid leukemia patients (AML) with the anti-killer-cell immunoglobulin-like receptor 
(KIR) mAb (Lirilumab® BMS), which inhibits the KIR2DL-1, -2 and -3 inhibitory receptors 
and their ligands, resulting in activated NK cells10. 
The objective of this study was to characterize the phenotype of intratumoral immune 
cells (tumor infiltrating lymphocytes; TILs) in RCC tumors derived from patients diagnosed 
with kidney cancer. Upon receiving freshly excised patient RCC tumors from nephrectomies, 
the samples were used for the immunophenotyping of the TILs. Also, we aimed to use in vitro 
methods to investigate the function of NK cells against RCC cell lines. The cells were further 
assessed using a real time killing assay for functional analyses of the cells.  
From our results, we have identified different immune profiles of the TILs, as well as 
observed the expression markers concerning the immune phenotype of RCC tumor cells. The 
characterization patterns of the cell populations expressing T, NK and tumor specific markers 
were analyzed, providing an immune profile regarding each RCC patient. Based on the 
results, we suggest that patients diagnosed with RCC possess unique immune profiles 
depending on the individual, but also share characteristics regarding the tumor. In addition, 
we have tested the functional aspects of RCC cancer cells in vitro by testing their cytotoxic 
abilities. From our results, we have concluded that NK cells have the potential to activate a 
cytotoxic response to RCC cells.  
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Materials and Methods 
 
 
Patients and samples 
The ongoing study included 13 RCC patients that underwent a surgical removal of the 
tumors, mostly via partial, or in some cases, radical nephrectomy. Tumor samples were 
collected and delivered directly from the University of Helsinki Hospital Comprehensive 
Cancer Center as well as from Peijas Hospital (Vantaa), as soon as the patient’s blood 
circulation was closed off. Physicians Harry Nisen and Petrus Järvinen were responsible in 
kindly providing us with the patient samples.    
 
 
Ethical considerations 
The approval for laboratory studies, collection of peripheral blood, tumor biopsies and RCC 
tumor samples has been obtained from the HUCH ethical committee (115/13/03/02/15). All 
patients gave a written informed consent and the study was approved by the local university 
hospitals (Meilahti and Peijas). In addition, the permission to perform the studies has been 
secured from the University of Helsinki Comprehensive Cancer Hospital. Subject anonymity 
has been guaranteed whereby each patient was given a number code for further use in the 
laboratory.  
 
 
Storage and handling of RCC tumor samples 
Each RCC tumor sample was collected in 50mL Falcon tubes containing 10 - 15mL MACS 
Tissue Storage Solution (Miltenyi Biotec). The sample was first weighed and photographed to 
measure the size and morphology. The tumors were then minced and homogenized according 
to Miltenyi’s Tumor Dissociation Kit protocol. After the tumors were homogenized, the 
viable cells were counted with the Sysmex XP-300TM automated hematology analyzer. After 
resuspending the sample in 1 x PBS, 500µL of the tumor cells were set aside for flow 
cytometric analysis. In total, four pellets between 1 – 107 (depending on the total cell count) 
cells were frozen in -70°C, whereby two were stored in the RNALater Solution (Invitrogen) 
and the other two frozen as pellets. The rest of the cells were live frozen in fetal bovine serum 
(FBS; Gibco) + 10% DMSO in 56 – 108 aliquots for later experiments. 
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Miltenyi Biotec tumor dissociation kit  
Tumors were dissociated into single-cell suspensions by mechanical and enzymatic digestion 
of the extracellular matrix. The gentleMACS™ Dissociator instrument was utilized for the 
mechanical degradation procedures (program for soft tumors). After the dissociation, the 
samples were applied to a filter to remove any larger particles from the single-cell 
suspensions and were resuspended in RPMI 1640 (LONZA) until further processing. The 
tumor cells were immediately processed for phenotyping the tumor cell population and 
downstream applications. The kit is designed for a simple yet effective generation of single-
cell suspensions using primary human tumor tissue.  
 
 
Multicellular tumor spheroids 
Solid, 3D tumor spheroids were generated using the A-498 and CAKI-1 RCC cell lines by 
seeding 3 cells/100uL per well in a volume of 100uL/well of culture medium in 96-well ultra-
low cluster, 96-well round bottom plates (Corning). The growth was monitored every two 
days after the third day of initial seeding (d0, d3, d5, d7…d30). The growth of the spheroids 
was monitored under a phase contrast microscope (Biorad) and imaged. The spheroids were 
left to grow until the diameters reached between 400 – 700µm in size.  
 
 
Cell culture 
Human renal cell carcinoma cell lines CAKI-1, CAKI-2, A498 were cultured in their 
corresponding media 80% McCoy’s 5a + 20% h.i. fetal bovine serum (FBS) for CAKI-1, 
CAKI-2, and 90% MEM (with Earle’s salts) + 10% FBS for A-498, respectively. The 
cytotoxic lymphocyte cell line, NK-92 was cultured in RPMI 1640 (LONZA) + 10ng/mL IL-
2. In addition, all the media were supplemented with 10% FBS 1% L-Glutamine (LONZA), 
1% Penicillin-Streptomycin (LONZA) and the cell lines were cultured at 37°C in 5% CO2. 
The human kidney carcinoma cell lines CAKI-1, CAKI-2 and A-498 were ordered from 
DSMZ, Germany, DSMZ no. ACC 731, ACC 54, and ACC 55, respectively. The cytotoxic 
NK-92 cell line was also ordered from DSMZ, Germany, DSMZ no. ACC 488.  
In addition, we used two human renal cell adenocarcinoma cell lines AHCN and 786-
O, kindly provided by Piia Mikkonen and Vilja Pietiäinen (Kallioniemi group, Institute of 
Molecular Medicine Finland (FIMM)). Both cell lines were cultured in RPMI 1640 (LONZA) 
media supplemented with 10% FBS, 1% L-Glutamine, 1% Penicillin-Streptomycin, at 37°C 
and 5% CO2. 
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Immunophenotyping of RCC tumors 
The RCC patient tumor samples were analyzed by an immunophenotyping assay using flow 
cytometry (BD FACS Verse) with a panel of fluorescently labeled antibodies that were 
specifically selected in order to characterize the phenotype of the NK, T, and tumor cells. The 
immunophenotyping antibody panel consisted of four tubes with specific antibodies and one 
unstained control (Table 1). All the antibodies were titrated in order to obtain the optimal 
volumes for their usage in the phenotyping assay (the volumes in µL for each antibody are 
presented in Table 1). For each tube, the antibodies and 100µL of the dissociated tumor 
sample were added. Then, the tubes were incubated in the dark for 15min at room 
temperature. After the incubation, the cells washed three times with 1mL of 1 x PBS via 
centrifugation (300g x 5 min), and resuspended in 300uL of 1 x PBS for analysis. The FACS 
Suite software was set to acquire 1 x 106 total events from each tube.  
 
Table 1 | Immunophenotyping panel 
All tubes contain antibodies to detect the main lymphocyte subpopulations (CD45 for 
lymphocytes, CD3 for T cells and CD56 for NK cells). Tube B1 Contains the immune 
checkpoint inhibitors PD-1 and LAG-3. PD-L1 and PD-L2 were also included to observe how 
much of the ligands were expressed in the RCC tumors. Tube B2 The CXC chemokine 
receptors CXCR3 and CXCR4 are markers were selected to observe the regulation and 
migratory behavior of the T and NK cells. The NK-specific marker CD16 is associated with 
antibody dependent cellular cytotoxicity (ADCC). Tube B3 The NKG2 family of proteins is 
mostly expressed on the surface of naïve NK cells responsible for the NK cell activation, and 
DNAM-1 (CD226) indicates NK cell maturation. Tube B4 c-Met and cytokeratin are markers 
targeting tumor cells. 7-AAD was included as a common cell viability marker.  
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Real-time cell impedance and cytotoxicity assay  
The iCelligenceTM instrument monitors the electrical impedance in a noninvasive manner to 
quantify the proliferation, morphology change, and attachment quality of cells in a label-free, 
real-time condition. The killing assay (real-time) was initially performed using, human renal 
cell carcinoma and later, renal cell adenocarcinoma cell lines. The A-498, CAKI-1, CAKI-2 
(carcinoma), and AHCN, 786-O (adenocarcinoma) lines were used as targets to see the 
cytotoxic effects of the effector NK-92 cells.  
In the assay, the cellular impedance (CI) of the adherent target cells growing at the 
bottom of the RTCA iCelligenceTM (ACEA Biosciences, Inc) plates was measured. In this 
system, cellular growth and proliferation corresponds to an increase in the CI, whereas a 
decrease in CI would signify cell death and/or detachment from the plates.  
The killing assay was initiated by resetting the instrument (executing one sweep with 
395µL of the corresponding cell line media). Two sessions (first target, later target and 
effector cells), each with 1440 total sweeps per minute for a total of 24h was measured (Table 
2). After reset, 50 000 adherent target cells x 8 wells / plate were seeded (5µL of 107/ mL cell 
suspension) via reverse pipetting, totaling a volume of 395uL in each of the wells. The target 
cells were cultured for 24h at 37°C in 5% CO2 to obtain fully confluent wells. After 24h, 
200µL of the old media was removed from the wells. The effector cells were then added 
according to the effector to target (E:T) ratio (Table 3), and the total volume re-adjusted to 
400µL by adding the appropriate volume of fresh cell media. The effectors and targets were 
co-cultured for 24h, in which the target CI was measured every minute. 
 
Table 2 | iCelligence killing assay in real-time  
 
Step Sweeps Duration Interval 
Reset 1/1 1min 1min 
Target Cells 1440/1440 24h 1min 
Target-Effector 1440/1440 24h 1min 
The iCelligence instrument was reset before seeding the target cells. After system reset, the 
target cells were seeded and the impedance measured every minute for 24h to obtain a 
confluent monolayer of cells. On the following day, the effector cells were added to the wells 
and were co-incubated for 24h, with the impedance being measured every minute.  
 
First, a dose-response with NK-92 effector cells against the A-498, AHCN, CAKI-1, 
CAKI-2 and 786-O cell lines as the target cells were measured to test the suitability of NK-
mediated cell killing. The NK-92 cell line is known to have cytotoxic features and originates 
from a rare NK-cell lymphoma patient that enables the NK cells to grow continuously11. The 
E:T ratios (Table 3) were obtained from the literature12 
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Table 3 | Effector to target ratios used in the killing assay  
 
Effector to target (E:T) ratios used in the direct killing assays 
Target cells tested: A-498, CAKI-1, CAKI-2, AHCN, 786-O 
Effector cells: NK-92 
 Target Effector  
Target control 50 000 50 000 
Effector control 50 000 50 000 
4:1 200 000:50 000 200 000:50 000 
   
8:1 400 000:50 000 400 000:50 000 
   
16:1 800 000:50 000 800 000:50 000 
   
*The E:T ratios were carried out in duplicates to ensure consistency of the results  
 
 
iCelligenceTM functional assay 
The cellular impedance (CI) from the iCelligence assay was analyzed using the RTCA 
iCelligence Software (ACEA Biosciences). The impedance curve was first normalized to the 
last measured impedance of the cultured target cells before the addition of the effectors. The 
cytotoxic activity percentage after the 24h of co-incubation at a given effector to target (E:T) 
ratio was counted in Excel by the following equation13:  
Cytotoxic Activity % = (1 – CI24hE:T / CI24h control) x 100  
After normalizing and counting the cytotoxic activity percentage, the data was converted to a 
CSV file and uploaded to Prism GraphPad for statistical analysis and graphing. 
 
 
Data analysis 
The immunophenotyping data was analyzed with the FlowJo software by gating cell 
populations expressing the specific surface marker antigens (Fig. 1). The gating strategy from 
the initial flow cytometric data was initiated by first observing the total cell population using 
side scatter channel (SSC, y-axis) vs forward scatter channel (FSC, x-axis) plot. In flow 
cytometry, the amount of light scattered by the cells is measured at right angles to the laser 
beam (SSC) and forward direction (FSC). The size, morphology and optical homogeneity of 
the cells affect how much of the light is scattered. The fluorochromes in each tube were 
designed to delineate the different cell populations. After the gating process of different cell 
populations, the statistics were exported to FlowJo through Excel that were then converted to 
the CSV file format and linked with the Prism GraphPad Software to result in the final 
graphing of the data.  
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Figure 1A | Gating of the cell populations using FlowJo  
First, the SSC vs FSC plot was used to select the live cells out of the total cell population 
(excluding the granulocytes). The CD45+ lymphocytes were gated next. From the CD45+ 
population, the NK cells were gated as CD3-CD56+bright and CD3-CD56+dim cell 
populations. In addition, the total NK (dim and bright) were gated to see the total NK cell 
population. The CD3+CD56- T cells were gated in order to differentiate between the CD8- 
(CD4+) and CD8+ T cells. Figure 1A shows the gating strategy for peripheral blood (healthy 
control).  
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Figure 1B | Gating of the RCC tumor samples 
The tumor samples were gated in a similar fashion as the peripheral blood. In addition, the 
CD4+CD8- and CD4-CD8+ populations were delineated in Tube B2 to avoid false positive 
and negative populations. The rest of the tubes from the antibody panel included the markers 
for CD3+ and CD8- that were then assumed as CD4+ T cells.  
 
 
 
	 11	
Figure 1C | Expressions of specific receptors and surface markers were gated identically 
between different cell populations based on negative populations 
All the antibody markers in the CD4+ T, CD8+ T and CD56+ NK cells were gated in a 
consistent and identical fashion with reference to the negative cell populations. Here, the 
expression of PD-1 is demonstrated by gating the marker in the NK (CD3-CD56+ bright, 
dim), CD8- and CD8+ populations in a RCC patient sample.  
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Results 
 
 
RCC tumor characteristics 
A total of 13 patient RCC tumor samples were received thus far and analyzed according to 
their size (diameter in mm) and weight (g) to distinguish the physical characteristics (Fig. 
2.1). The median weight and diameter of the tumors were 3g (range 1.39-6.25g) and 22mm 
(range 15-33mm), accordingly (Fig. 2.2 a,b). The surgical nephrectomy procedure was kept 
consistent for all RCC patients, although exceptional cases are also present. 
 
Figure 2.1 | 13 RCC patient tumor samples have been collected thus far and were analyzed 
according to the tumor diameter and weight.  
                                                                                                   
 
 
 
                                                                                                
 
 
 
After the tumor was homogenized and dissociated (tumor dissociation kit, see 
materials and methods), a portion of the cells was immunophenotyped by flow cytometric 
analysis (approximately 0.5 x 106 cells per tube). Then, the cells were further processed so 
that first, the lymphocyte population of cells could be gated. Next, the subpopulations of the 
lymphocytes (CD45+) in the population was isolated according to a distinct population that 
could be observed from the size of the CD45+ cell population in the SSC – CD45+ plot (see 
Fig 1b) according to the FlowJo gating strategy. The lymphocytes from the tumor were first 
gated from the live cell population that excluded the granulocytes and calculated from all total 
events; the CD45+ lymphocytes were then calculated from the lymphocyte live gate. 7.29% 
of the CD45+ lymphocyte population was obtained from the initial gating of the cells (Fig 
2.2c). 
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Figure 2.2 | RCC tumor characteristics  
Each tumor before the immunophenotyping assay was weighed (g) and its diameter (mm) 
measured (a, b). During the flow cytometry analysis, the (c) The CD45+ lymphocyte 
population (mean = 7.29%) was gated from the initial cell population. 
 
 
  
 
The immunophenotype of TILs show an active phenotype in RCC patients 
The patient-derived RCC samples were immunophenotyped by first homogenizing the tumor 
and staining the cells according to a specific antibody panel (Table 1) targeting NK, T cell 
and tumor-specific markers. The expressions were measured using flow cytometry. In order 
to gate and delineate the different cell populations expressing different surface antigens, the 
FlowJo software was used (Fig. 3). Out of the CD45+ lymphocytes, 37% were T cells and 
10.8% NK cells on average (Fig. 3b, c). From the CD45+ lymphocyte population, the patients 
that had a high proportion of lymphocytes were grouped separately to see whether a similar 
pattern could be seen for the T and NK cells in the same patients. This was however not the 
case, as a high proportion of CD45+ lymphocytes did not indicate a large proportion of T and 
NK cells (Fig. 3a-c).  
Consequently, we then analyzed the different TILs and their subset populations, 
namely the different CD4+, CD8+ T cells, and the CD56bright and CD56dim NK cells. 
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Amongst the T cell population, a higher percentage of CD4+CD8- cells were observed than 
the CD4-CD8+ cell population. Thus it can be concluded that there were more T helper and T 
memory (CD4+) cells in the RCC patient samples rather than the cytotoxic T cells (CD8+), 
indicating a higher CD4/CD8 ratio. From the total number of NK cells in the CD45+ 
lymphocytes, our results are concordant with the literature that states a higher amount of 
CD56 dim cells (Fig. 3i; mean = 14.19) are naturally present than CD56 bright NK subsets 
(Fig. 3h; mean = 1.91)14.   
 
Figure 3 | Immunophenotype of TILs in RCC patient tumor samples  
The homogenized tumor sample was stained with the antibody panel targeting the cells of 
interest (NK-, T-, and tumor-specific markers) and their expressions observed. (a) Green dots 
represent the patient samples that had the highest amount of the lymphocyte population from 
the flow cytometric analysis to see whether the amount of lymphocytes in the tumor was 
correlative to the amount of (b) T and (c) NK cell populations. (d) The T cells are divided 
into (e) CD4+CD8- and (f) CD4-CD8+ populations. (g) The NK cell population was divided 
into two subsets, (h) CD56bright and (i) CD56dim NK cell subpopulations gated from the 
CD45+ lymphocytes.   
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Immune checkpoint markers are expressed in RCC TILs 
We investigated whether the patients with high expressions of PD-1 (green) also expressed 
high levels of other immune checkpoint markers, LAG-3, PD-L1 and PD-L2. Our results 
indicate that patients with a high expression in PD-1 do not express high levels of other 
immune checkpoint markers such as LAG-3 (Fig. 4a, b). The same can be said for the NK 
subset populations. Of particular note are the low expression levels of PD-1 and LAG-3 in the 
CD56bright as opposed to the higher expressions in the CD56dim NK subset (Fig. 4c, d). 
 
PD-1/LAG-3 double positive expression 
 We were also interested in observing the PD-1/LAG-3 double positive expressions in 
the TILs (Fig 4e). PD1 was highly expressed in both CD8+ and CD4+ T cells, but the highest 
amount of double positive cells was seen amongst the CD8+ T cell population (approximately 
10% of the CD8+ T cells), known as the main effector of anti-tumor responses15. 
 
Figure 4 | Expression of immune checkpoint markers in TILs 
In this figure, the expression profiles of the RCC immune cells involving the mAbs PD-1, 
LAG-3, and the PD-L family of markers are shown for (a) CD8+ T cells, (b) CD4+ T cells, 
(c) CD56bright NK cells, and (d) CD56dim NK cells. Figure (e) shows the LAG-3/PD-1 
double positive expression in T (CD8+, CD8-) and NK (CD56bright, CD56 dim) cell subsets. 
The double positive expression occurs the highest in the CD8+ T cell population. 
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CXC chemokine receptor expression in RCC tumors 
To further characterize the intratumoral lymphocytes, we analyzed the CXC chemokine 
receptor expressions (CXCR3 and CXCR4) in the RCC tumors (Fig. 5). The CXCR3 
expression varied amongst the patients. Of particular note, the CD56bright NK cells hardly 
expressed the CXCR3 receptor, whereas the CD56dim cells showed a higher amount of 
expression (Fig 5a). Also, a higher proportion of the patients expressed CXCR4 as opposed to 
CXCR3 in both T and NK cells (Fig 5b). Although CXCR3 expression is highly variable in 
the T cells, the expression of CXCR4 follows an increased and similar pattern of expression 
amongst the RCC tumors.  
 
CD16 is highly expressed in NK cells 
Next, we looked at the CD16 expression in both subsets of the NK cells (Fig 5c). 
CD16 is a low affinity receptor (FcγRIII) that binds to the constant Fc chain of the antibody, 
activates the NK cells, and induces antibody-dependent cellular cytotoxicity (ADCC), 
resulting in lysis of the target cell16, 17. Our results indicate that CD16 is thus expressed in 
both NK subsets and more in the CD56dim subpopulation. 
 
 
 
Figure 5 | Expression profiling of the RCC tumor cells involving the CXC chemokine 
receptors and CD16 markers 
(a) The percentage CXCR3 expression given for T (CD8-, CD8+) and NK (CD56bright, 
CD56dim) cells. Our results indicate a higher expression of CXCR3 in T cells when 
compared to the expression in the NK cell subsets. (b) CXCR4 expression is also higher in T 
cells when compared to NK cells, with similar patterns of expression in the T cell 
populations. (c) CD16 is highly expressed in both NK subsets.   
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Markers of NK cell activation 
Although markers such as DNAM and CD57 showed variable expressions on the T and NK 
cells, their patterns of distribution can further be divided into subpopulations amongst the 
patients. An elevated expression of DNAM could be observed when compared to CD57 (Fig. 
6a, b), indicative of activation in the natural cytotoxicity receptor. CD57 is a marker for 
highly differentiated NK cells18. The expression pattern was observed to be similar between 
the CD8- T cells and CD56bright NK population.  
Next, we looked at the NKG2 family of receptors involved in NK cell receptor 
activation. The NK cell populations showed a high expression of the NKG2A marker (Fig. 
6c). With respect to NKG2D expression, only a small subset of cells expressed the marker in 
the CD4+CD8- T cells (Fig. 6d), which is agreeable with the literature showing that only a 
small population of CD4+ T cells naturally express NKG2D19. The CD8+ T cells and the 
CD56dim NK cells also showed distinct subgroups of the patients that expressed high and 
low levels of the NKG2D marker. 
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Figure 6 | Expression profiling of the RCC tumor cells involving the NKG2 family, 
DNAM and CD57 markers  
(a) DNAM expression in the different lymphocyte subpopulations. The highest expression 
could be seen for the CD8- T and CD56dim NK cells. (b) CD57 expression varied between 
patients. (c) Higher NKG2A expression in NK cell subsets than in T cells. Many RCC tumors 
indicate a similar pattern of expression in T cells. (d) Low NKG2D expression in CD8- T 
cells was observed compared to CD8+ T cells.  
 
 
 
Tumor specific markers and their immune profiles 
In our uniquely designed antibody panel (Table 1), the final tube (B4) consisted of the 
markers that were selectively included to target the tumor cells from the rest of the cells in the 
sample. Also, the gating of the cells was done in a similar fashion as above so that the 
lymphocytes and tumor cells could be differentiated. It should be noted that the RCC tumors 
were transported to our facilities for processing as soon as the circulation of the nephrectomy 
was cut off to ensure maximal cell viability. Our results show that the majority of the cells 
obtained were viable based on the viability marker, 7-AAD (mean = 87.63%; Fig. 7b). The 
viable cells were then divided to CD45+ leukocytes and CD45- cell populations, which 
presumably consisted mostly of the tumor cells (Fig. c, d). The majority of cells were CD45-, 
thus being mostly tumor and stromal cells (mean = 90.8%; Fig. 7d). 
 Next, we wanted to test the lymphocytic and tumor cell subpopulations with tumor-
specific markers in order to observe their immunophenotypes. To our surprise, the cytokeratin 
and C-Met staining was also observed in CD45+ lymphocytes (Fig. 7e, f). Although C-Met is 
considered to be critical in playing a role in the growth of RCC by increasing PD-L1 
expression and anti-apoptotic signals20, the expression of the marker was low in most of the 
CD8+ CD8- CD56bright CD56dim
0
20
40
60
80
%
 D
N
A
M
 e
xp
re
ss
io
n
DNAM
c d
CD8+ CD8- CD56bright CD56dim
0
20
40
60
80
%
 N
K
G
2A
 e
xp
re
ss
io
n
NKG2A
CD8+ CD8- CD56bright CD56dim
0
20
40
60
80
%
 N
K
G
2D
 e
xp
re
ss
io
n
NKG2D
CD8+ CD8- CD56bright CD56dim
0
20
40
60
80
%
 C
D
57
 e
xp
re
ss
io
n
CD57
a b
	 19	
tumor cells. In addition, most of the tumor cells expressed low amounts of cytokeratin, a 
marker associated with the differential diagnosis of renal tumors20 (Fig. 7f). Further analyses 
are needed to clarify the specificities of the antibodies. 
 
 
Figure 7 | Tumor-specific markers and their expression profiles from the RCC tumor 
cells  
(a) From the total cells, we gated the negative and positive cell populations (dead and live, 
respectively) using the FlowJo software. (b) The CD45+ lymphocytes and (c) CD45- 
population that contains the tumor and stromal cells. (e) Expression of tumor cell markers on 
the CD45+ lymphocytes and (f) on the CD45- cells that were presumed to contain tumor 
cells. 
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RCC cell lines are able to grow into 3D spheroids in vitro 
In order to create an in vitro experiment where we could grow tumor 3D models, spheroids 
using RCC cell lines were cultured and their morphologies observed. After the fourth day of 
seeding, the single-cell suspensions of the RCC cell lines A-498 and CAKI-1 were able to 
grow in each well, whereby a spherical structure could be observed under a phase-contrast 
microscope. Consequently, the spheroids maintained their form and structure for the 
remainder of the days in which their growths were followed. Owing to the different cell lines, 
the A-498 cells were smaller in size (mean = 300µm) and maintained a circular structure (Fig. 
8A). The CAKI-1 cells on the other hand, grew to a more spherical, blooming structure (Fig. 
8B), and were larger in diameter (mean = 700µm).   
 After a 30-day analysis of the cells, many of the cellular suspensions became 
contaminated and were not viable. Under the microscope, it could be observed that the cells 
became necrotic or could no longer be visualized, due to the contaminated environment of the 
plate wells. Out of the 96 wells of the plate, half of the plates were seeded with A-498 and the 
other half with CAKI-1 cells. After a 30-day observation, less than 50% of the seeded cells 
discontinued their growth or survived. However, the remaining cells were still able to retain 
their size and morphology. Our results confirmed the 3D spheroids could be grown in vitro 
from RCC cell lines.   
 
Figure 8 | 3D tumor spheroid model, A-498 and CAKI-1 
The RCC cell lines A-498 and CAKI-1 were plated as single cell suspensions per well. Their 
size and morphology were followed after seeding. As a result, the cells were able to form 
spheroids from approximately the fifth day of plating the cells. The size and morphology of 
the cells remained consistent during and after their growth for 30 days (from left to right: d3, 
d5, d7…d30). 
 
Figure 8A | 3D tumor spheroid model, A-498 
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Figure 8B | 3D tumor spheroid model, CAKI-1 
 
 
RCC cell lines are sensitive to NK cell-mediated cytotoxicity  
The target RCC cell lines A-498, CAKI-1, CAKI-2, AHCN and 786-O were tested by co-
incubating them with the cytotoxic NK-92 cell line to see whether they were suitable for NK 
cell-mediated killing. The cell lines were initially plated in duplicate ratios using the 
iCelligence 8-well plates and were incubated overnight so that a monolayer of the cells could 
form. After a 24h incubation period, the effector NK-92 cell lines were plated together with 
the target cells and incubated for another 24h in order to fully observe their cytotoxic effects.  
The results indicate that the NK-92 cells were able to effectively kill each target cell 
line. Furthermore, this cytotoxic activity is increased with higher E:T ratios (Fig. 9). The 
cytotoxic events may be observed by comparing the control well, whereby only the target 
cells were plated. Here, the cellular impedance (CI) steadily increases over time, indicating 
cellular proliferation and confluence. Similar curves were observed for the cytotoxic activity 
in the cell lines. As the E:T ratios increased (4:1, 8:1, 16:1), the cytotoxic effects of the NK-
92 cells increased, in which the greatest cytotoxicity could be observed with the highest E:T 
ratio. The cytotoxic function of the effector cells with the 4:1 and 8:1 ratios did not have a 
vast difference towards the target cells, although it could be clearly seen that the increased 
E:T ratio resulted in more cytotoxic behavior. Out of the various RCC cell lines that were 
tested, the 786-O cells showed the most vigorous cytotoxic effect (Fig. 9e). From our 
observations, the target and effector cell lines were confirmed to be suitable for the direct 
cytotoxic assay.   
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Figure 9 | Cytotoxic activity of the NK-92 (effector) cell line towards the RCC (target) 
cell lines  
The effector and target cell lines were co-incubated for 24h in which the CI was measured 
every minute. Each E:T ratio was plated as duplicates (line and dotted lines). The normalized 
CI increases in the control well, indicating target cell growth. The CI decreases in the E:T 
wells according to the increasing E:T ratios, indicating an increase in cytotoxic activity.  
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Discussion 
 
 
Our adaptive and innate immune systems have shown the potential to clear cancer. Targeting 
immune checkpoints, and thus activating the immune system to kill cancer, have become a 
promising treatment option for cancer immunotherapy in a variety of different cancers, 
starting from metastatic melanoma and further, to RCC among others. This type of therapy 
aims to show good clinical response as well as benefit the overall patient survival rate. 
Despite this hope, the immune checkpoint proteins that we know so far such as PD-1 only 
make up a tiny piece of the puzzle out of a plethora of ligands and receptors that may be 
potential immunotherapy targets. Immune checkpoint pathways that are dominant in the 
tumor microenvironment are key players in the identification of potential immuno-
oncological biomarkers. In order for their detection, it would be crucial to determine which 
pathways are commanding the particular tumor. Likewise, other challenges remain, such as 
the need to improve the combinatorial effects of the therapy in the clinical environment. 
Monotherapies such as anti-PD-1 are deemed more efficacious when combined with other 
forms of targeted therapies such as the use of vaccines that will provide further antitumor 
immunity7. In addition, NK cells have the ability to potentiate strong antitumor activity, but 
their importance and influence are yet to be explored further.  
 
The unique tumor immunophenotype of each RCC patient 
The regulation of T cell function is known to be involved in an array of mechanisms 
including the activation of coinhibitory molecules that suppress the signaling pathways. One 
such set of signals is mediated by programmed death protein 1 (PD-1) and programmed death 
ligand 1 (PD-L1) that are part of the CD28/CTLA-4 (cytotoxic T-lymphocyte-associated 
protein 4) family and are activated in T cells. Upon binding with its ligands, PD-L1 and PD-
L2 become negative regulators of T cell receptor (TCR) signaling, decreasing T cell 
proliferation and cytokine production3. 
PD-1 is thus responsible for the downregulation of the immune system and promotes 
self-tolerance by suppressing T cell-induced inflammatory activity. From our results, we 
observed that the high expression of PD-1 does not correspond to similar expression levels for 
other immune checkpoint molecules such as LAG-3 (Fig. 4). In addition, the low PD-1 
expression observed in the CD56bright NK cells did not signify similar expression levels for 
the CD56dim NK subsets (Fig. 4c, d). In-depth functional studies targeting the different NK 
cell subsets and their significance in expressing different levels the immune checkpoint 
markers are further needed. We also explored the PD-1 and LAG-3 double positive 
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expressions in the TILs, and noticed that the highest expression occurs in CD8+ T cells (Fig. 
4e). Further analyses are needed to investigate whether the combination of the proteins may 
serve as a possible prognostic marker for RCC similarly, as is the case in patients diagnosed 
with triple negative breast cancer and express both checkpoint receptors15.  
The CXC chemokine receptors CXCR3 and CXCR4 are markers that are mainly 
expressed in B, T and NK cells and are responsible in regulating the migration of cells. Here, 
we were particularly interested in the migration of T and NK cells. A high expression of 
CXCR4 could be seen in most of the patient tumors (Fig. 5). This may be due to the fact that 
CXCR4 is a functional receptor that is upregulated in cancerous cells compared to healthy 
tissue21. It has also previously been shown that CXCR4 expression is correlated with the 
metastatic potential of RCCs, and is overexpressed in primary tumors22. The high expression 
may thus be correlative to an increased tendency of the RCC tumors to metastasize outside 
the kidney. CD16 is considered to have constitutive expression in CD56dim NK cells that 
may in turn result in an increased number of FcγRIII-bearing NK cells and enhance their 
activation16. For solid tumors, the loss of CD16 in tumor infiltrating NK cells is associated 
with the loss of NK cell-tumor engagement, diminished tumor recognition and cytotoxicity 
ADCC16, 17. In our study, we observed that CD16 was expressed in both NK cell subsets (Fig. 
5c). 
The NKG2 family of proteins is mostly expressed on the surface of naïve NK cells 
and is responsible for the activation of NK cells19. In healthy cells, the receptors are tightly 
regulated in order to prevent autoimmune and self-recognition reactivity. We observed a 
heightened expression pattern in the NK cells of the RCC patient tumors for the NKG2A 
receptor compared to the T cells (Fig. 6c). A follow-up study comparing the circulating NK 
cells in the blood from the same patients before (tumor) and after (peripheral blood) their 
surgery would be one method to see a difference in the expressions of the marker. Also, 
NKG2D is expressed in all CD8+ T cells, on most NK cells, and only in a subset of CD4+ T 
cells25. Our results are in accordance with this indicating a low expression of NKG2D in the 
CD4+ T cells and high expression of the marker in all CD8+ T cells of the RCC patient 
tumors (Fig. 6d). We also observed a subgroup of patients whose CD8+ T cells and CD56dim 
NK cells had particularly high expression of NKG2D, which may be an indication of 
inflammation19, 25. 
With regards to targeting the lymphocytic and tumor cell subpopulations, we added 
the c-Met marker into our antibody panel. C-Met is known as tyrosine-protein kinase Met, 
whereby mutations in the MET gene are commonly associated with papillary RCCs. Also, c-
Met serves as a prognostic marker and potential therapeutic target in RCC26. Together with 
cytokeratin, these two antibodies were considered as markers for tumor cells, as we wanted to 
observe how many tumor cells were in each sample. However, it seemed that the antibodies 
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also bound to lymphocytes and therefore, the panel needs further optimization of the tumor-
specific markers that will directly and specifically target the tumor cells. One solution would 
be to add more immunomarkers that concern kidney tumors, such as cytokeratin 18 (CK18) 
which is positively expressed in all major types of renal tumors, and ‘RCC marker (the 
commercial name by Vector Laboratories Inc),’ a mAb directed against a glycoprotein found 
in the brush border of healthy renal proximal tubular cells27.   
So far, targeting the PD-1 and PD-L1 blockade has shown the most promise in the 
treatment of solid tumors, including RCC with noticeable antitumor effects, increased 
treatment responses and overall survival rates of the patients28. In melanoma patients, anti-
PD-1 acts as lymphocyte activators, in which the inhibitory signals to the checkpoint 
inhibitor, PD-1 are blocked. This effect enables the cytotoxic T cells to regain their cytotoxic 
capabilities against the cancer. Because anti-PD-1 is known to restore antitumor T cell 
functioning in melanoma, this effect may also be observed in renal cancers. However, one 
aspect of research would be to further investigate how anti-PD-1 treatment affects the NK 
cells and their cytotoxic ability. Although the enhancing effects of anti-PD-1 to NK cell 
mediated cytotoxic activity has been reported for in vitro studies using NK cells derived from 
myeloma patients29, further research is needed in exploring the effects on the 
immunophenotype of NK cells, as well as on the functional activities the cells have in vivo for 
patients treated with anti-PD-1.  
Our results showed that RCC patients have variable immune checkpoint expressions 
in their TILs. One example is the variability in PD-1 expression, as some patients had high 
expressions of the marker, whereas others had low expression. Another interesting phenotype 
was the PD-1 and LAG-3 double positive cells. Further research is needed to assess the 
patients who express high levels of both markers, providing potential candidates for 
combinatorial therapies and better predictors of patient screening for future clinical trials. The 
highly unique aspects of the immune profiles as well as the shared tumor characteristics shed 
more insight on the future of immuno-oncological therapies and possibly, new breakthroughs 
for biomarker studies.  
 
NK cells possess cytotoxic activity against RCC 
To measure the cytotoxic potential of the NK-92 cell line against the RCC cell lines, the real 
time killing assay was used. This method could be further applied in testing the RCC patients’ 
NK cells towards the target cell lines. Our results are in accordance with the literature that has 
shown that NK cells are able to target and kill cancer cells without pre-stimulation13. The 
differences observed in the killing activities of the NK-92 effector cells against the different 
target cell lines may be due to the variability in morphology, growth and doubling time. This 
is due to the instrument’s impedance-based characteristics in measuring the different types of 
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adherent cells that have attached to the bottom of the wells. Also, the interactions between the 
target and effector cells might unleash different molecular interactions that may inhibit or 
slow down the killing process. Another factor that could be accountable for the different 
readouts may be due to the variable immunogenic characteristics between the cell lines, and 
this should be further studied (such as the expression of various ligands that activate and/or 
inhibit NK cell receptors).  
Follow up studies involving the cytotoxic potentials of in vivo patient NK cells are 
much needed. One aspect to keep in mind would be the tumor microenvironment, and how it 
can affect the tumor cells as well as the tumor infiltrating immune cells. Other factors include 
epigenetic and environmental factors, such as age and smoking. Renal cancers are very much 
age-related, whereby the stage of onset and diagnosis occurs later in life and among the 
elderly. Furthermore, it should be noted that the immune system varies greatly with age (such 
as the reduced diversity of T cells in the elderly30), providing further evidence for the loss of 
immune cell control in older people. It has also been observed that smokers are liable to 
having low NK and immunoglobulin numbers, which may affect their overall immune 
systems and ability to fight off certain diseases31. With this in mind, the number of patients in 
our study is currently too small to compare the effect of age on the different immune cells.  
 We also noticed that there is considerable inter-individual variation among the RCC 
patients. However, the depth of the variation is still yet unclear and needs detailed analyses 
using multiplexed systems such as mass cytometry. By considering these inter-dependent 
components of the immune system, we may be able to further explore the co-variation 
between health and disease31. Recent cohort studies have already shown great variability in 
the immune cell frequencies in healthy adults, such as the frequency of CD4+ T cells ranging 
between 22 – 90%; CD8+ T cells between 6 – 65%; and NK cells, 0 – 59%32, 33. The 
observation that healthy individuals possess such a wide degree of variation in immune cells 
suggests novel studies for the future.      
 
3D ex vivo tumor models 
The preliminary data from the in vitro spheroid models suggest that the growth and 
monitoring of the RCC cell lines are possible. However, the model still lacks various 
optimization steps until various immune checkpoint inhibitors and TIL-associated markers 
can be tested. We are currently exploring another 3D tumor model using patient-derived RCC 
cells, which would greatly improve our research aims in testing the functional characteristics, 
as well as to analyze cell-to-cell contacts for future assays.  
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Patient pre-surgery and follow-up samples 
To characterize further the TILs and RCC tumor cells, we hope to receive peripheral blood 
samples in addition to the tumor tissue both pre- and post-surgery. Analyses between the 
immunophenotypic expressions before the surgery as well as after the patient’s recovery 
would be vital in comparing them with the results that we have managed to get from the 
tumor immune profiles thus far.  
 
In conclusion, we have characterized the immune phenotypes of the patient-derived RCC 
tumor cells and TILs with various immune checkpoint markers. Based on our preliminary 
phenotypic data and cytotoxicity assays, we state that NK cells have the potential to become 
actively cytolytic, and potentially enhance the antitumor immunity by acting on the RCC cells 
in vitro. Our results also indicate that there are unique inter-individual differences between 
the patients. Further analyses and a larger number of patients are necessary components to 
compare the differences and shared characteristics between the tumor and blood samples. In 
the future, we hope to broaden our knowledge in comparing and distinguishing the 
fundamental roles of the two cytotoxic lymphocytes, the NK and T cells, as well as their roles 
in the clearance of cancer under the influence of immune checkpoint inhibitors. 
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